Akèy › Sarkom tisi mou › Massachusetts
Etid klinik pou Sarkom tisi mou nan Massachusetts
19 etid pou Sarkom tisi mou ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610Anti-GD2 ADC M3554 in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06641908Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05732831First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06644755Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05711615A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06760819Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04188535Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 15 a 39 · Tout sèks · Mizajou Aug 26, 2026 · NCT07662239STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06975293Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07059884NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- Brigham and Women's Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT07377747Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT07675967Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT05225428Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Ap rekriteFaz 1/2
Laj 12 a 49 · Tout sèks · Mizajou Feb 19, 2026 · NCT06709495A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT04370587REtroperitoneal SArcoma Registry: an International Prospective Initiative
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 12, 2019 · NCT03838718Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.